Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LUCAR-G79D T cells · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Chimeric antigen receptor T cells (LUCAR-G79D) | EXPERIMENTAL | Each subject will be given a single-dose LUCAR-G79D cells infusion at each dose level. |
| Name | Type | Description |
|---|---|---|
| LUCAR-G79D T cells | BIOLOGICAL | Prior to infusion of the LUCAR-G79D T cells, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine. |
Inclusion Criteria: 1. Subjects voluntary agreement to provide written informed consent. 2. Aged 18 to 70 years, either sex. 3. Adequate organ function meet screening criteria. 4. Positive test for cluster of differentiation antigen 19 (CD19). SLE: * Have been diagnosed of SLE at least 6 months b...
Top 20 of 32 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biogen Inc. | BIIB | 5 | PHASE3 | Litifilimab |
| Bristol-Myers Squibb Company | BMY | 7 | PHASE3 | Deucravacitinib |
| Viatris, Inc. | VTRS | 5 | PHASE3 | Cenerimod |
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Ianalumab |
| AstraZeneca PLC | AZN | 21 | PHASE3 | Medi-546 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Nipocalimab |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Belimumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | SAR441344 |
| Zenas BioPharma, Inc. | ZBIO | 1 | PHASE2 | Obexelimab |
| Alumis Inc. | ALMS | 1 | PHASE2 | Envudeucitinib |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Fate Therapeutics, Inc. | FATE | 2 | PHASE2 | FT819 |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY4298445 |
| Cartesian Therapeutics, Inc. | RNAC | 2 | PHASE2 | Descartes-08 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-1045 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | KITE-363, Fludarabine, Cyclophosphamide |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE1 | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
LUCAR-G79D T cells is an investigational cell therapy being studied for the treatment of relapsed/refractory Systemic Lupus Erythematosus (SLE) and Idiopathic Inflammatory Myopathies (IIM). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
LUCAR-G79D T cells is being developed by Legend Biotech Corporation, a biopharmaceutical company traded on the Nasdaq under the ticker LEGN. The company is conducting a Phase 1 clinical trial of this investigational therapy in China.
LUCAR-G79D T cells is in Phase 1 clinical development. It is an investigational therapy, meaning it has not been approved by regulatory authorities and is still being evaluated in clinical trials for safety and efficacy.
LUCAR-G79D T cells is being studied in a Phase 1 clinical trial identified as NCT07331272. This trial is recruiting participants with relapsed/refractory Systemic Lupus Erythematosus and Idiopathic Inflammatory Myopathies, with an enrollment target of 38 participants in China.
LUCAR-G79D T cells is not FDA approved. It is an investigational therapy currently in Phase 1 clinical development, meaning it has not yet been approved by the FDA or any other regulatory authority for commercial use.